Medtronic PLC MDT
We take great care to ensure that the data presented and summarized in this overview for Medtronic plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDT
View all-
Vanguard Group Inc Valley Forge, PA127MShares$11.4 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY112MShares$10.1 Billion0.2% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.41 Billion0.21% of portfolio
-
Capital Research Global Investors Los Angeles, CA31.7MShares$2.85 Billion0.56% of portfolio
-
Jpmorgan Chase & CO New York, NY28.6MShares$2.57 Billion0.2% of portfolio
-
Morgan Stanley New York, NY28.3MShares$2.54 Billion0.17% of portfolio
-
Geode Capital Management, LLC Boston, MA26.9MShares$2.41 Billion0.19% of portfolio
-
Massachusetts Financial Services CO Boston, MA24.8MShares$2.23 Billion0.62% of portfolio
-
Bank Of America Corp Charlotte, NC21.5MShares$1.93 Billion0.15% of portfolio
-
Wellington Management Group LLP Boston, MA21.2MShares$1.91 Billion0.3% of portfolio
Latest Institutional Activity in MDT
Top Purchases
Top Sells
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Insider Transactions at MDT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 20
2024
|
Michael Marinaro EVP & President, Surgical OU |
SELL
Payment of exercise price or tax liability
|
Direct |
2,045
-4.82%
|
$173,825
$85.38 P/Share
|
Aug 15
2024
|
Gary Louis Corona Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
8,966
+21.35%
|
-
|
Aug 02
2024
|
Gregory L Smith EVP Global Ops & Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
2,887
-2.25%
|
$233,847
$81.51 P/Share
|
Aug 02
2024
|
Gregory L Smith EVP Global Ops & Supply Chain |
BUY
Exercise of conversion of derivative security
|
Direct |
3,490
+5.11%
|
-
|
Aug 02
2024
|
Matthew R. Walter SVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
441
-0.86%
|
$35,721
$81.51 P/Share
|
Aug 02
2024
|
Matthew R. Walter SVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
684
+2.57%
|
-
|
Aug 02
2024
|
Brett A. Wall EVP & Pres Neuroscience |
SELL
Payment of exercise price or tax liability
|
Direct |
5,063
-5.29%
|
$410,103
$81.51 P/Share
|
Aug 02
2024
|
Brett A. Wall EVP & Pres Neuroscience |
BUY
Exercise of conversion of derivative security
|
Direct |
5,311
+9.75%
|
-
|
Aug 02
2024
|
Ivan K Fong EVP GENERAL COUNSEL & SECR |
SELL
Payment of exercise price or tax liability
|
Direct |
9,210
-4.97%
|
$746,010
$81.51 P/Share
|
Aug 02
2024
|
Ivan K Fong EVP GENERAL COUNSEL & SECR |
BUY
Exercise of conversion of derivative security
|
Direct |
14,514
+10.43%
|
-
|
Aug 02
2024
|
Jennifer M Kirk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
476
-0.82%
|
$38,556
$81.51 P/Share
|
Aug 02
2024
|
Jennifer M Kirk Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,138
+3.78%
|
-
|
Aug 02
2024
|
Michael Marinaro EVP & President, Surgical OU |
SELL
Payment of exercise price or tax liability
|
Direct |
1,410
-1.62%
|
$114,210
$81.51 P/Share
|
Aug 02
2024
|
Michael Marinaro EVP & President, Surgical OU |
BUY
Exercise of conversion of derivative security
|
Direct |
1,670
+3.67%
|
-
|
Aug 02
2024
|
Geoffrey Martha Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,172
-4.58%
|
$1,471,932
$81.51 P/Share
|
Aug 02
2024
|
Geoffrey Martha Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,966
+8.54%
|
-
|
Aug 02
2024
|
Karen L Parkhill EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,729
-6.5%
|
$545,049
$81.51 P/Share
|
Aug 02
2024
|
Karen L Parkhill EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,132
+11.77%
|
-
|
Aug 02
2024
|
Sean Salmon EVP & President Cardiovascular |
SELL
Payment of exercise price or tax liability
|
Direct |
3,436
-2.53%
|
$278,316
$81.51 P/Share
|
Aug 02
2024
|
Sean Salmon EVP & President Cardiovascular |
BUY
Exercise of conversion of derivative security
|
Direct |
5,462
+7.38%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 162K shares |
---|---|
Exercise of conversion of derivative security | 109K shares |
Payment of exercise price or tax liability | 58.6K shares |
---|---|
Open market or private sale | 55.7K shares |